{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"0"}]}],"title":"Stringent Complete Response (sCR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"17"}]}],"title":"Complete Response (CR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"33"}]}],"title":"Very Good Partial Response (VGPR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"17"}]}],"title":"Partial Response (PR)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"description":"Partial Response \\[PR\\], Very Good Partial Response \\[VGPR\\], Complete Response \\[CR\\], and stringent Complete Response \\[sCR\\] were assessed by the investigator per IMWG (2016). PR defined as ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \\<200 mg/24 h. VGPR defined as serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \\<100 mg/24 h. CR defined as negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \\<5% plasmacytomas in the bone marrow. sCR defined as CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.","groups":[{"description":"Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 1.9 milligram (mg)/kilogram (kg) of belantamab mafodotin intravenous (IV) infusion in combination with 8 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin end of infusion (EOI), once every 3 weeks (Q3W).","id":"OG000","title":"1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab"},{"description":"Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion in combination with 8 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin EOI Q3W.","id":"OG001","title":"2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab"},{"description":"Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion in combination with 24 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin EOI Q3W.","id":"OG002","title":"2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab"}],"paramType":"NUMBER","populationDescription":"Safety population","reportingStatus":"POSTED","timeFrame":"Up to approximately 281 weeks.","title":"DE Phase: Percentage of Participants Achieving Stringent Complete Response (SCR), Complete Response (CR), Very Good Partial Response (VGPR) and Partial Response (PR)","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}